JAK2 and myeloproliferative disorder: And yet, from the initial discovery of the JAK2 V617F mutation as a key driver in the majority of MPN patients, it is increasing clear that many more subtleties determine the overall disease phenotype, prognosis and whether “disease” develops at all.